

Lyon, May 6, 2026

---

## Institut Mérieux increases its stake in bioMérieux

---

Following a meeting held on April 27 under the chairmanship of Alain Mérieux, the Board of Directors of Institut Mérieux approved the acquisition of an additional 1% stake in bioMérieux, thereby increasing its shareholding and reaffirming its confidence in the Group's strategic direction and role as a world leader in *in vitro* diagnostics.

As a result of this acquisition, Institut Mérieux now holds close to 60% of bioMérieux's share capital.

*"This share purchase confirms of our long-term support and confidence in bioMérieux's strategic and operational roadmap as well as in the dedication of our talented teams" said Alexandre Mérieux, Vice Chairman of the Board of Directors of Institut Mérieux and Chairman of the Board of Directors of bioMérieux. "bioMérieux has a clear ambition to accelerate sustainable and profitable growth by leveraging breakthrough innovation in diagnostics, strengthening operational excellence, and expanding its global impact. As a majority shareholder, Institut Mérieux is fully aligned with this strategy and remains deeply committed to supporting bioMérieux in its mission to serve public health and improve patient care worldwide".*

### About Institut Mérieux

For nearly 130 years, Institut Mérieux has been committed to serving global public health. The Group oversees companies with complementary activities in *in vitro* diagnostics, food safety, immunotherapy, and health investments. It is the majority shareholder in four companies that form the core of its bioindustrial group: bioMérieux, Mérieux NutriSciences, Transgene, and Mérieux Equity Partners. The Group brings together 26,000 people in more than 50 countries, while maintaining a strong base in France. Institut Mérieux is also a committed shareholder of two other companies, Ceva and OXB.

### About bioMérieux

#### *Pioneering Diagnostics*

A world leader in the field of *in vitro* diagnostics for 60 years, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

### Press contact

Image 7 for Institut Mérieux :  
Isabelle de Segonzac - +33 6 89 87 61 39 - [isegonzac@image7.fr](mailto:isegonzac@image7.fr)

#### PRESS CONTACT

Mail: [communication@institut-merieux.com](mailto:communication@institut-merieux.com)

Tel: +33 (0)4 78 87 70 70

[www.institut-merieux.com](http://www.institut-merieux.com)

